Florian Fintelmann, M.D.
|
Associate Professor of Radiology Harvard Medical School |
|
Clinicn Investigator, Assc Prf Rad AMC Thoracic Faculty M, Mass General Research Institute |
|
Radiologist Thoracic Imaging and Intervention, Massachusetts General Hospital |
|
Medical Director of Thoracic Radiology Thoracic Imaging and Intervention, Massachusetts General Hospital |
| MD 2006 |
Research Interests
Research Narrative
Dr. Fintelmann is a physician-scientist at Massachusetts General Hospital (MGH) and an Associate Professor of Radiology at Harvard Medical School. He completed Radiology Residency and Fellowship training at MGH, including dedicated training in interventional radiology. He currently serves as Medical Director of Thoracic Radiology at MGH and heads the thoracic percutaneous ablation program at MGH.
As the head of Thoracic Percutaneous Thermal Ablation at Massachusetts General Hospital, Dr. Fintelmann is integrated into the Thoracic Cancer Team. His research focuses on improving cancer care with advanced imaging techniques and image-guided minimally invasive interventions.
Dr. Fintelmann studies the spectrum of lung cancer imaging manifestations, ranging from early diagnosis (lung cancer screening with low-dose chest computed tomography) to advanced disease. Dr. Fintelmann co-leads a multi-disciplinary team studying cancer cachexia and is using quantitative image analysis to improve the risk stratification of patients with cancer for appropriate therapies. His lab is leveraging machine learning tools to extract morphometric data, including body composition, from computed tomography exams of the chest and abdomen obtained as part of routine clinical care.
Dr. Fintelmann believes that patients with cancer benefit from interventional oncology and is working on furthering the role of minimally invasive image-guided diagnostic and therapeutic procedures. Specifically, he is studying percutaneous ablation (cryoablation, microwave ablation) and needle biopsies. Dr. Fintelmann advocates for percutaneous ablation to treat lung cancer in patients with interstitial lung disease and recurrent lung cancer following radiation therapy. Ongoing clinical trials in collaboration with the MGH Cancer Center investigate possible synergy between immunotherapy and cryoablation in patients with advanced lung cancer and advanced melanoma (cryoimmunotherapy, cryoimmunology).
Collaborators
https://fintelmannlab.mgh.harvard.edu/
Grant Funding
Society of Interventional Oncology
William M. Wood Foundation
National Institutes of Health
| fintelmann@mgh.harvard.edu |
| 6177244254 |
|
Radiology 55 Fruit Street Boston, MA 02114 |